Abstract

ABSTRACT Introduction Heme oxygenase 1 (HMOX1) is a key enzyme involved in the heme metabolism. HMOX1 expression may be induced by oxidative stress and cytokines, and there is increasing evidence that it may exert cytoprotective effects and facilitate survival and growth of some tumor cells. Aim: The aim of our study was to analyze whether clinical outcome of ovarian cancer patients subjected to standard therapeutic procedures may be associated with the functional -413A > T single nucleotide polymorphism (SNP) within the promoter of HMOX1 gene. Methods The study included 135 patients (median age, 54 years; 95% CI, 39-69) with stage I-IV epithelial ovarian cancer who underwent cytoreductive surgery followed by standard paclitaxel/platinum analogue chemotherapy. Patients DNA was routinely isolated from the peripheral blood and -413A > T SNP was genotyped using specific SNP Genotyping Assay (Applied Biosystems). Results The respective frequencies of -413A > T SNP AA, AT and TT genotypes within the patients' group were 34.1% (46/135), 46.7% (63/135) and 19.3% (26/135) and were similar to distribution within the general population control group. Kaplan-Meier analysis has revealed that AA genotype was associated with significantly longer progression free survival time. The median progression free survival time was 22.2 months in AA harboring patients and 14.5 months in patients with AT + TT genotype (p = 0.033 by log-rank test). AA genotype was also significantly associated with longer overall survival time. Three-year overall survival in AA and AT + TT group was 77.9% and 52.5%, respectively (p = 0.014). Conclusions The results of our study show for the first time that response to the first line treatment and clinical outcome of ovarian cancer patients with standard paclitaxel/platinum analogue chemotherapy might be associated with functional -413A > T SNP in the HMOX1 gene. This finding may be of practical importance for prognostication and may suggest that HMOX-1 is a potential target for a supportive clinical intervention. Disclosure All authors have declared no conflicts of interest.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.